Literature DB >> 15722335

Cytoplasmic and nuclear retained DMPK mRNAs are targets for RNA interference in myotonic dystrophy cells.

Marc-André Langlois1, Christelle Boniface, Gang Wang, Jessica Alluin, Paul M Salvaterra, Jack Puymirat, John J Rossi, Nan Sook Lee.   

Abstract

Small interfering RNA (siRNA) duplexes induce the specific cleavage of target RNAs in mammalian cells. Their involvement in down-regulation of gene expression is termed RNA interference (RNAi). It is widely believed that RNAi predominates in the cytoplasm. We report here the co-existence of cytoplasmic and nuclear RNAi phenomena in primary human myotonic dystrophy type 1 (DM1) cells by targeting myotonic dystrophy protein kinase (DMPK) mRNAs. Heterozygote DM1 myoblasts from a human DM1 fetus produce a nuclear retained mutant DMPK transcript with large CUG repeats ( approximately 3,200) from one allele of the DMPK gene and a wild type transcript with 18 CUG repeats, thus providing for both a nuclear and cytoplasmic expression profile to be evaluated. We demonstrate here for the first time down-regulation of the endogenous nuclear retained mutant DMPK mRNAs targeted with lentivirus-delivered short hairpin RNAs (shRNAs). This nuclear RNAi(-like) phenomenon was not observed when synthetic siRNAs were delivered by cationic lipids, suggesting either a link between processing of the shRNA and nuclear import or a separate pathway for processing shRNAs in the nuclei. Our observation of simultaneous RNAi on both cytoplasmic and nuclear retained DMPK has important implications for post-transcriptional gene regulation in both compartments of mammalian cells.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15722335     DOI: 10.1074/jbc.M501591200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  45 in total

Review 1.  Peptides in cancer nanomedicine: drug carriers, targeting ligands and protease substrates.

Authors:  Xiao-Xiang Zhang; Henry S Eden; Xiaoyuan Chen
Journal:  J Control Release       Date:  2011-10-26       Impact factor: 9.776

2.  Reducing levels of toxic RNA with small molecules.

Authors:  Leslie A Coonrod; Masayuki Nakamori; Wenli Wang; Samuel Carrell; Cameron L Hilton; Micah J Bodner; Ruth B Siboni; Aaron G Docter; Michael M Haley; Charles A Thornton; J Andrew Berglund
Journal:  ACS Chem Biol       Date:  2013-09-27       Impact factor: 5.100

Review 3.  Epigenetic changes and non-coding expanded repeats.

Authors:  Masayuki Nakamori; Charles Thornton
Journal:  Neurobiol Dis       Date:  2010-02-18       Impact factor: 5.996

4.  Why a positive genetic test for myotonic dystrophy type I does not always imply the right diagnosis.

Authors:  S G Meuth; C Kleinschnitz; M Frank; C Wessig; M Bendszus; W Kress; H Wiendl
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-12       Impact factor: 10.154

5.  siRNA in human cells selectively localizes to target RNA sites.

Authors:  Svitlana Y Berezhna; Lubica Supekova; Frantisek Supek; Peter G Schultz; Ashok A Deniz
Journal:  Proc Natl Acad Sci U S A       Date:  2006-05-09       Impact factor: 11.205

6.  Stable suppression of gene expression by short interfering RNAs targeted to promoter in a mouse embryonal carcinoma stem cell line.

Authors:  Fariba Esmaeili; Taravat Bamdad; Sorayya Ghasemi
Journal:  In Vitro Cell Dev Biol Anim       Date:  2010-09-25       Impact factor: 2.416

7.  Triplet-repeat oligonucleotide-mediated reversal of RNA toxicity in myotonic dystrophy.

Authors:  Susan A M Mulders; Walther J A A van den Broek; Thurman M Wheeler; Huib J E Croes; Petra van Kuik-Romeijn; Sjef J de Kimpe; Denis Furling; Gerard J Platenburg; Geneviève Gourdon; Charles A Thornton; Bé Wieringa; Derick G Wansink
Journal:  Proc Natl Acad Sci U S A       Date:  2009-08-10       Impact factor: 11.205

8.  CRM1 mediates nuclear-cytoplasmic shuttling of mature microRNAs.

Authors:  Daniela Castanotto; Robert Lingeman; Arthur D Riggs; John J Rossi
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-02       Impact factor: 11.205

Review 9.  The miRNA pathway in neurological and skeletal muscle disease: implications for pathogenesis and therapy.

Authors:  Christopher R Sibley; Matthew J A Wood
Journal:  J Mol Med (Berl)       Date:  2011-07-13       Impact factor: 4.599

Review 10.  Antisense oligonucleotides: rising stars in eliminating RNA toxicity in myotonic dystrophy.

Authors:  Zhihua Gao; Thomas A Cooper
Journal:  Hum Gene Ther       Date:  2013-01-30       Impact factor: 5.695

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.